STAAR SURGICAL CO 8K

STAAR Surgical reported a strong Q2 2026 rebound with more than doubled sales, a return to profitability, and significant China-led growth, supported by operational and strategic investments.

STAAR Surgical Company reported its second quarter 2026 results, announcing net sales of $93.5 million (up 111% year-over-year, driven primarily by a sharp rebound and market share gains in China), a return to profitability with net income of $8.1 million or $0.16 per diluted share versus a loss a year ago, and Adjusted EBITDA of $20.0 million, while highlighting strong demand for EVO ICL procedures across APAC, the Americas, and EMEA (ex-Middle East), the successful implementation of a new ERP system, ongoing investments in supply chain and innovation, and the CEO’s strategic focus on revenue growth, margin expansion, and platform development for lens-based refractive surgery.

Filing Facts

CIK

718937

Ticker

-

Form

8K

Source Type

sec

Accession

0000718937-26-000036

Alert Tier

7